Skip to main content

Generic Yupelri Availability

Last updated on Oct 6, 2021.

Yupelri is a brand name of revefenacin, approved by the FDA in the following formulation(s):

YUPELRI (revefenacin - solution;inhalation)

  • Manufacturer: MYLAN IRELAND LTD
    Approval date: November 9, 2018
    Strength(s): 175MCG/3ML [RLD]

Has a generic version of Yupelri been approved?

No. There is currently no therapeutically equivalent version of Yupelri available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Yupelri. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 10,106,503
    Issued: October 23, 2018
    Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLC

    This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

    Patent expiration dates:

    • March 10, 2025
      ✓ 
      Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 10,343,995
    Issued: July 9, 2019
    Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLC

    This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

    Patent expiration dates:

    • March 10, 2025
      ✓ 
      Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Patent 10,550,081

    Patent expiration dates:

    • July 14, 2030
      ✓ 
      Drug substance
  • Patent 11,008,289

    Patent expiration dates:

    • July 14, 2030
      ✓ 
      Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 7,288,657
    Issued: October 30, 2007
    Inventor(s): Mammen; Mathai & Ji; Yu-Hua & Mu; YongQi & Husfeld; Craig & Li; Li
    Assignee(s): Theravance, Inc.

    This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

    Patent expiration dates:

    • December 23, 2025
      ✓ 
      Drug substance
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 7,491,736
    Issued: February 17, 2009
    Inventor(s): Mammen; Mathai & Ji; Yu-Hua & Mu; YongQi & Husfeld; Craig & Li; Li
    Assignee(s): Theravance, Inc.

    This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

    Patent expiration dates:

    • March 10, 2025
      ✓ 
      Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 7,521,041
    Issued: April 21, 2009
    Inventor(s): Mammen; Mathai & Ji; Yu-Hua & Mu; YongQi & Husfeld; Craig & Li; Li
    Assignee(s): Theravance, Inc.

    This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

    Patent expiration dates:

    • March 10, 2025
      ✓ 
      Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 7,550,595
    Issued: June 23, 2009
    Inventor(s): Mammen; Mathai & Ji; Yu-Hua & Mu; YongQi & Husfeld; Craig & Li; Li
    Assignee(s): Theravance, Inc.

    This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

    Patent expiration dates:

    • March 10, 2025
      ✓ 
      Drug product
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 7,585,879
    Issued: September 8, 2009
    Inventor(s): Mammen; Mathai & Ji; Yu-Hua & Mu; YongQi & Husfeld; Craig & Li; Li
    Assignee(s): Theravance, Inc.

    This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

    Patent expiration dates:

    • March 10, 2025
      ✓ 
      Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 7,910,608
    Issued: March 22, 2011
    Inventor(s): Mammen; Mathai & Ji; Yu-Hua & Mu; YongQi & Husfeld; Craig & Li; Li
    Assignee(s): Theravance, Inc.

    This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

    Patent expiration dates:

    • March 10, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 8,034,946
    Issued: October 11, 2011
    Inventor(s): Mammen; Mathai & Ji; YuHua & Mu; YongQi & Husfeld; Craig & Li; Li
    Assignee(s): Theravance, Inc.

    This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

    Patent expiration dates:

    • March 10, 2025
      ✓ 
      Drug product
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 8,053,448
    Issued: November 8, 2011
    Inventor(s): Mammen; Mathai & Ji; YuHua & Mu; YongQi & Husfeld; Craig & Li; Li
    Assignee(s): Theravance, Inc.

    This invention provides methods of using compounds of formula Ib below to treat pulmonary disorders. wherein: R4 is hydrogen or (1-4C)alkyl; q is 0, 1, or 2; R5 is independently selected from halo, (1-4C)alkyl, and (1-4C)alkoxy, wherein each alkyl and alkoxy group is optionally substituted with from 1 to 3 fluoro substituents; R7 is hydrogen or (1-4C)alkyl; or a pharmaceuticallly acceptable salt thereof.

    Patent expiration dates:

    • March 10, 2025
      ✓ 
      Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent 8,273,894
    Issued: September 25, 2012
    Inventor(s): Mammen; Mathai & Ji; YuHua & Mu; YongQi & Husfeld; Craig & Li; Li
    Assignee(s): Theravance, Inc.

    This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

    Patent expiration dates:

    • March 10, 2025
      ✓ 
      Drug product
  • Crystalline freebase forms of a biphenyl compound
    Patent 8,541,451
    Issued: September 24, 2013
    Assignee(s): Theravance, Inc.

    The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.

    Patent expiration dates:

    • August 25, 2031
      ✓ 
      Drug substance
  • Crystalline freebase forms of a biphenyl compound
    Patent 9,765,028
    Issued: September 19, 2017
    Assignee(s): Theravance Biopharma R&D IP, LLC

    The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.

    Patent expiration dates:

    • July 14, 2030
      ✓ 
      Drug substance

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • November 9, 2023 - NEW CHEMICAL ENTITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.